These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 2762260)

  • 1. [Comparative evaluation of the effectiveness of vitamin D3 preparations (1-alpha-hydroxy- and 1-alpha,25-dihydroxycholecalciferol in various forms of osteoporosis and osteomalacia].
    Zarubina NA; Rozhinskaia LIa; Bukhman AI; Dorokhova II; Konnova EV
    Probl Endokrinol (Mosk); 1989; 35(3):15-9. PubMed ID: 2762260
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Treatment of patients with postmenopausal osteoporosis and steroid-induced osteoporosis with the preparation Rocaltrol (1,25/OH/2 vitamin D3)].
    Koev D; Todorova S; Diankov L; Khristova D; Tsachev K
    Vutr Boles; 1988; 27(2):117-22. PubMed ID: 3414094
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of vitamin D resistant hypophosphataemic osteomalacia with 1alpha-hydroxy vitamin D3.
    Peacock M; Heyburn PJ; Aaron JE
    Calcif Tissue Res; 1977 May; 22 Suppl():55-62. PubMed ID: 912585
    [No Abstract]   [Full Text] [Related]  

  • 4. Long-term treatment of postmenopausal osteoporosis with active vitamin D3, 1-alpha-hydroxycholecalciferol (1 alpha-OHD3) and 1, 24 Dihydroxycholecalciferol (1, 24(OH)2D3).
    Shiraki M; Orimo H; Ito H; Akiguchi I; Nakao J; Takahashi R; Ishizuka S
    Endocrinol Jpn; 1985 Apr; 32(2):305-15. PubMed ID: 2995014
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The action of 1alphahydroxy vitamin D3 and phosphate supplements in hypophosphataemic osteomalacia.
    Peacock M; Aaron JE; Heyburn PJ; Nordin BE
    Adv Exp Med Biol; 1977; 81():431-40. PubMed ID: 899935
    [No Abstract]   [Full Text] [Related]  

  • 6. Vitamin D metabolites and bone mineralization in man.
    Bordier P; Rasmussen H; Marie P; Miravet L; Gueris J; Ryckwaert A
    J Clin Endocrinol Metab; 1978 Feb; 46(2):284-94. PubMed ID: 750606
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Parenteral 1,25-dihydroxycholecalciferol in hepatic osteomalacia.
    Long RG; Varghese Z; Meinhard EA; Skinner RK; Wills MR; Sherlock S
    Br Med J; 1978 Jan; 1(6105):75-7. PubMed ID: 620204
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metabolites of vitamin D in human vitamin-D deficiency: effect of vitamin D3 or 1,25-dihydroxycholecalciferol.
    Papapoulos SE; Clemens TL; Fraher LJ; Gleed J; O'Riordan JL
    Lancet; 1980 Sep; 2(8195 pt 1):612-5. PubMed ID: 6107407
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Experience in treating metabolic osteopathies with 1 alpha-hydroxyvitamin D3 (oksidevit)].
    Babarykin DA; Reĭsner NA; Riabukha AN; Rozental' RL
    Ter Arkh; 1991; 63(11):113-6. PubMed ID: 1810042
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adult-onset vitamin D-resistant osteomalacia with the unresponsiveness to parathyroid hormone.
    Fujita T; Nomura M; Okajima S; Furuya H
    J Clin Endocrinol Metab; 1980 May; 50(5):927-31. PubMed ID: 6246136
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Changes in mineral metabolism in stage 3, 4, and 5 chronic kidney disease (not on dialysis)].
    Lorenzo Sellares V; Torregrosa V
    Nefrologia; 2008; 28 Suppl 3():67-78. PubMed ID: 19018742
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Short-term effects of varying doses of 1 alpha-hydroxyvitamin D3 on blood and urine chemistry and calcium absorption of osteoporotic patients.
    Lindholm TS; Sevastikoglou JA; Lindgren U
    Clin Orthop Relat Res; 1978 Sep; (135):226-31. PubMed ID: 709935
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of phenytoin on bone and vitamin D metabolism.
    Bell RD; Pak CY; Zerwekh J; Barilla DE; Vasko M
    Ann Neurol; 1979 Apr; 5(4):374-8. PubMed ID: 220903
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Treatment of severe postmenopausal osteoporosis].
    Reĭsner NA; Babarykin DA; Vorona IG; Riabukha AN; Rozental' RL
    Probl Endokrinol (Mosk); 1988; 34(4):13-6. PubMed ID: 3194355
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biochemical and histological effects of 1,25 dihydroxycholecalciferol (1,25-DHCC) in the osteomalacia of chronic and failure.
    Eastwood JB; Phillips ME; de Wardener HE; Bordier J; Marie P; Arnaud CD; Norman AW
    J Urol Nephrol (Paris); 1974 Dec; 80(12):984-5. PubMed ID: 4617780
    [No Abstract]   [Full Text] [Related]  

  • 16. Short-term effects of 1-alpha-hydroxy-vitamin D3 in patients on corticosteroid treatment and in patients with senile osteoporosis.
    Lindgren U; Lindholm S; Sarby B
    Acta Med Scand; 1978; 204(1-2):89-92. PubMed ID: 685736
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Results of long-term treatment of osteoporosis with 1 alpha-hydroxyvitamin D3 and calcium.
    Lindholm TS; Eriksson S; Lindholm TC
    Ital J Orthop Traumatol; 1984 Jun; 10(2):187-201. PubMed ID: 6432736
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vitamin D resistant hypophosphataemic osteomalacia: treatment with 1alpha-hydroxyvitamin D3.
    Peacock M; Heyburn PJ; Aaron JE
    Clin Endocrinol (Oxf); 1977 Dec; 7 Suppl():231s-237s. PubMed ID: 203418
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bone mineral and calcium metabolism before, during and after treatment of osteoporosis with 1 alpha-hydroxyvitamin D3 and calcium.
    Lindholm TS; Eriksson S
    Scand J Rheumatol; 1982; 11(1):55-7. PubMed ID: 7063813
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Diagnosis of anticonvulsant osteomalacia in adults (author's transl)].
    Krause KH; Prager P; Schmidt-Gayk H; Ritz E
    Dtsch Med Wochenschr; 1977 Dec; 102(51):1872-7. PubMed ID: 598289
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.